1.67

4.37% 0.07

After Hours: 1.65 -0.02 -1.20%

Prokidney Corp (PROK)

Overview News Price History Option Chain Financials Discussions Forecast

Prokidney Corp stock is traded at $1.67, with a volume of 348.67K. It is up +4.37% in the last 24 hours and down -4.30% over the past month. ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.

Previous Close:

$1.60

Open:

$1.64

24h Volume:

348.67K

Relative Volume:

0.77

Market Cap:

$218.19M

Revenue:

Net Income/Loss:

$-35.47M

P/E Ratio:

-2.9298

EPS:

-0.57

Net Cash Flow:

$-124.27M

1W Performance:

-1.76%

1M Performance:

-4.30%

6M Performance:

-24.77%

1Y Performance:

+19.29%

1-Day Range:

$1.6178

$1.73

1-Week Range:

$1.565

$1.82

52-Week Range:

$1.18

$4.44

Prokidney Corp Stock (PROK) Company Profile

Name

Prokidney Corp

Sector

Healthcare (1178)

Industry

Biotechnology (678)

Phone

336-999-7028

Address

2000 FRONTIS PLAZA BLVD., WINSTON-SALEM

Employee

163

Twitter

Next Earnings Date

2024-12-09

Latest SEC Filings

PROK's Discussions on Twitter

Compare PROK with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PROK Prokidney Corp	1.67	218.19M	0	-35.47M	-124.27M	-0.57
VRTX Vertex Pharmaceuticals Inc	438.40	113.67B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	683.08	74.97B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	665.68	40.50B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	277.16	35.95B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	120.88	29.63B	3.30B	-501.07M	1.03B	-2.1146

Prokidney Corp Stock (PROK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-30-24	Initiated	JP Morgan	Neutral
Sep-10-24	Initiated	Guggenheim	Buy
Mar-07-24	Resumed	Morgan Stanley	Equal-Weight
Jan-02-24	Downgrade	BofA Securities	Buy → Neutral
Jul-25-23	Initiated	BTIG Research	Buy
Dec-21-22	Initiated	Jefferies	Buy
Nov-10-22	Initiated	Morgan Stanley	Equal-Weight
Oct-18-22	Initiated	UBS	Buy
Oct-14-22	Initiated	Citigroup	Buy
Sep-23-22	Initiated	BofA Securities	Buy
Sep-02-22	Initiated	Evercore ISI	Outperform

View All

Prokidney Corp Stock (PROK) Latest News

Jan 27, 2025

US Penny Stocks: 3 Picks With Market Caps Under $300M - Simply Wall St

Jan 27, 2025

Jan 23, 2025

ProKidney secures out-of-market buyer, $20.5 million price tag for Greensboro site - The Business Journals

Jan 23, 2025

ProKidney's high-profile Greensboro plant initiative ends with planned $20 million sale of property - Winston-Salem Journal

Jan 23, 2025

Jan 22, 2025

ProKidney (NASDAQ:PROK) Trading 8.7% HigherStill a Buy? - MarketBeat

Jan 22, 2025

Insiders In ProKidney Still Down 26% On US$54.7m Investment - Simply Wall St

Jan 22, 2025

Jan 21, 2025

Barclays PLC Has $281,000 Position in ProKidney Corp. (NASDAQ:PROK) - Defense World

Jan 21, 2025

Jan 20, 2025

568,647 Shares in ProKidney Corp. (NASDAQ:PROK) Purchased by Hennion & Walsh Asset Management Inc. - MarketBeat

Jan 20, 2025

Jan 16, 2025

Jane Street Group LLC Has $78,000 Stock Holdings in ProKidney Corp. (NASDAQ:PROK) - Defense World

Jan 16, 2025

Jan 09, 2025